Education
About Us
Working with TipRanks
Follow Us
SOPHiA GENETICS (SOPH)
NASDAQ:SOPH
SOPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.58 - $4.92
Previous CloseN/A
Volume4.05K
Average Volume (3M)74.23K
Market Cap
$209.85M
Enterprise Value$177.69M
Total Cash (Recent Filing)$94.82M
Total Debt (Recent Filing)$63.81M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Nov 11, 2025EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding66,831,070
10 Day Avg. Volume149,517
30 Day Avg. Volume74,235
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.10
Price to Sales (P/S)3.11
P/FCF Ratio-3.98
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue2.55
Enterprise Value/Gross Profit3.76
Enterprise Value/Ebitda-3.06
Forecast
1Y Price Target
$6.10Price Target Upside85.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Customer GrowthMomentum appears to be building as volume grew with 33 new core genomics customers implemented.
Market ExpansionUS market expansion continues, where revenue and volumes grew over 30%, indicating strong market penetration.
Bears Say
Financial PerformanceSophia turned in a relatively challenging 2024 as they drove 4% revenue growth while growing their volumes by 11%, which implies a 6-7% decline in revenue per analysis, which declined in part due to headwinds with biopharma customers.
Revenue ChallengesThe company faced several headwinds in 2024 resulting in below long-term trend growth, notably from a lower biopharma revenue ramp and disruptions in LATAM.
SOPHiA GENETICS News
SOPH FAQ
What was SOPHiA GENETICS’s price range in the past 12 months?
SOPHiA GENETICS lowest stock price was $2.58 and its highest was $4.92 in the past 12 months.
What is SOPHiA GENETICS’s market cap?
SOPHiA GENETICS’s market cap is $209.85M.
When is SOPHiA GENETICS’s upcoming earnings report date?
SOPHiA GENETICS’s upcoming earnings report date is Nov 11, 2025 which is in 87 days.
How were SOPHiA GENETICS’s earnings last quarter?
SOPHiA GENETICS released its earnings results on Aug 05, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.214 by -$0.116.
Is SOPHiA GENETICS overvalued?
According to Wall Street analysts SOPHiA GENETICS’s price is currently Undervalued.
Does SOPHiA GENETICS pay dividends?
SOPHiA GENETICS does not currently pay dividends.
What is SOPHiA GENETICS’s EPS estimate?
SOPHiA GENETICS’s EPS estimate is -0.23.
How many shares outstanding does SOPHiA GENETICS have?
SOPHiA GENETICS has 66,831,070 shares outstanding.
What happened to SOPHiA GENETICS’s price movement after its last earnings report?
SOPHiA GENETICS reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.214. Following the earnings report the stock price went up 3.636%.
Which hedge fund is a major shareholder of SOPHiA GENETICS?
Currently, no hedge funds are holding shares in SOPH
SOPHiA GENETICS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.10 (85.98% Upside)
$6.10 (85.98% Upside)
Blogger Sentiment
Bullish
SOPH Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.25%
12-Months-Change
Fundamentals
Return on Equity
-74.09%
Trailing 12-Months
Asset Growth
-1.92%
Trailing 12-Months
Company Description
SOPHiA GENETICS
SOPHiA GENETICS (SOPH) is a health technology company that leverages data-driven medicine to enhance and expedite the analysis of genomic and radiomic data. The company operates within the biotechnology and healthcare sectors, providing a cloud-based software platform that enables healthcare institutions to analyze complex medical data to deliver insights that can improve patient outcomes. SOPHiA GENETICS' core product, the SOPHiA DDM™ platform, is designed to facilitate the interpretation of genomic data, thereby supporting various applications in oncology, rare diseases, and other health conditions.
SOPH Company Deck
SOPH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a predominantly positive outlook with significant revenue growth, a record number of new customer signings, and the landmark AstraZeneca partnership. However, challenges persist with BioPharma revenue headwinds and increased operating expenses.View all SOPH earnings summariesSOPH Stock 12 Month Forecast
Average Price Target
$6.10
▲(85.98% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.14% Mutual Funds
3.84% Other Institutional Investors
94.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---